First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Inclusion criteria:

* Personally signed informed consent document.
* Male or female, age ≥18 years.
* Relapsed or refractory ROR1+ malignancies
* ECOG performance status ≤2.
* Adequate organ function.

  * Bilirubin ≤1.5 x ULN (unless Gilbert's syndrome).
  * AST and ALT ≤2.5 x ULN (if no hepatic CLL or MCL), or AST and ALT ≤5 x ULN (if hepatic CLL or MCL).
  * APTT and PT ≤1.5 x ULN.
  * ANC ≥0.5 x 10\^9 /L (without growth factors) and platelets ≥ 30 x 10\^9 /L (without transfusion).
  * Serum creatinine ≤2 x ULN.
  * Estimated creatinine clearance ≥30 mL/min.
* In females of childbearing potential, a negative serum pregnancy test.
* For both males and females, willingness to use adequate contraception.
* Willingness and ability to comply with study procedures.

Exclusion Criteria:

* Richter's transformation.
* CNS or leptomeningeal active disease.
* High tumour bulk as defined in the protocol.
* Allogeneic or autologous organ transplant within prior 6 months.
* Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura within 8 weeks of screening.
* Clinically significant neurological disease.
* Clinically significant cardiovascular disease or ECG abnormalities.
* Severe chronic lung disease.
* Positive test at Screening for HIV, hepatitis B or hepatitis C infection.
* Any other concurrent cancer or cancer treatments.
* Uncontrolled ongoing infection
* Recent major surgery
* Concurrent participation in another clinical trial, or experimental therapy within 5 half-lives of Screening
* Pregnant or currently breastfeeding.
* Any other medical condition that in the opinion of the investigator contraindicates participation in the study.